[go: up one dir, main page]

MX2023000041A - Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus. - Google Patents

Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus.

Info

Publication number
MX2023000041A
MX2023000041A MX2023000041A MX2023000041A MX2023000041A MX 2023000041 A MX2023000041 A MX 2023000041A MX 2023000041 A MX2023000041 A MX 2023000041A MX 2023000041 A MX2023000041 A MX 2023000041A MX 2023000041 A MX2023000041 A MX 2023000041A
Authority
MX
Mexico
Prior art keywords
immune response
inducing
coronavirus
methods
compositions
Prior art date
Application number
MX2023000041A
Other languages
English (en)
Inventor
Peter C Demuth
Martin P Steinbuck
Lochana M Seenappa
Christopher M Haqq
Lisa Mcneil
Original Assignee
Elicio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elicio Therapeutics Inc filed Critical Elicio Therapeutics Inc
Publication of MX2023000041A publication Critical patent/MX2023000041A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describen anfífilos de CpG y antígenos de coronavirus (por ejemplo, una proteína de espícula de coronavirus, un péptido de la misma o una secuencia de ácido nucleico que codifica para la misma) para inducir una respuesta inmunitaria en un sujeto, y métodos de administración de anfífilos de CpG y antígenos de coronavirus (por ejemplo, una proteína de espícula de coronavirus, un péptido de la misma, una proteína de nucleocápside de coronavirus, un péptido de la misma o una secuencia de ácido nucleico que codifica para la misma), una proteína de espícula de coronavirus, un péptido de la misma, una proteína nucleocápside de coronavirus, un péptido de la misma, o una secuencia de ácido nucleico que codifica para la misma) para inducir una respuesta inmunitaria en un sujeto.
MX2023000041A 2020-06-26 2021-06-25 Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus. MX2023000041A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063044773P 2020-06-26 2020-06-26
US202063064836P 2020-08-12 2020-08-12
US202063124200P 2020-12-11 2020-12-11
US202163145200P 2021-02-03 2021-02-03
PCT/US2021/039134 WO2021263131A1 (en) 2020-06-26 2021-06-25 Compositions and methods for inducing an immune response against coronavirus

Publications (1)

Publication Number Publication Date
MX2023000041A true MX2023000041A (es) 2023-03-10

Family

ID=79281915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000041A MX2023000041A (es) 2020-06-26 2021-06-25 Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus.

Country Status (9)

Country Link
US (1) US20230263882A1 (es)
EP (1) EP4171574A4 (es)
JP (1) JP2023532290A (es)
KR (1) KR20230044404A (es)
AU (1) AU2021294342A1 (es)
BR (1) BR112022026580A2 (es)
CA (1) CA3183735A1 (es)
MX (1) MX2023000041A (es)
WO (1) WO2021263131A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI884296B (zh) * 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
US20240066114A1 (en) * 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
US20230190920A1 (en) * 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
WO2023159081A2 (en) * 2022-02-15 2023-08-24 Ohio State Innovation Foundation Nanotechnology based intranasal vaccine for covid-19
CN114752631B (zh) * 2022-06-15 2022-09-02 中国人民解放军军事科学院军事医学研究院 Rna及包含其的新型冠状病毒疫苗和制备方法
WO2024226775A2 (en) * 2023-04-26 2024-10-31 Elicio Therapeutics, Inc. Compositions containing polynucleotide and polypeptide amphiphiles and methods of use thereof
WO2025240477A1 (en) * 2024-05-17 2025-11-20 The Regents Of The University Of California Methods and materials for enhancing delivery of nucleic acid to cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1629104A4 (en) * 2003-06-04 2006-11-02 Bioleaders Corp CELL SURFACE EXPRESSION VECTOR OF SARS VIRUS ANTIGEN AND TRANSFORMED MICROORGANISMS
JP4691495B2 (ja) * 2004-07-15 2011-06-01 一般財団法人化学及血清療法研究所 コロナウイルススパイクｓ１融合蛋白及びその発現ベクター
ES2731524T3 (es) * 2012-04-05 2019-11-15 Massachusetts Inst Technology Composiciones inmunoestimuladoras y métodos de uso de las mismas
CN105792843B (zh) * 2013-11-29 2020-02-28 泰尔茂株式会社 佐剂组合物及包含其的疫苗组合物、以及它们的制造方法
CA3092693A1 (en) * 2018-03-02 2019-09-06 Elicio Therapeutics, Inc. Cpg amphiphiles and uses thereof
IL295377A (en) * 2020-02-07 2022-10-01 Modernatx Inc sars-cov-2 mRNA domain vaccines

Also Published As

Publication number Publication date
US20230263882A1 (en) 2023-08-24
WO2021263131A1 (en) 2021-12-30
JP2023532290A (ja) 2023-07-27
AU2021294342A1 (en) 2023-02-23
EP4171574A1 (en) 2023-05-03
BR112022026580A2 (pt) 2023-01-24
CA3183735A1 (en) 2021-12-30
EP4171574A4 (en) 2024-10-23
KR20230044404A (ko) 2023-04-04

Similar Documents

Publication Publication Date Title
MX2023000041A (es) Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus.
MX2024009072A (es) Vacuna contra el coronavirus.
PH12021550580A1 (en) African swine fever virus vaccine
Boyoglu-Barnum et al. Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice
WO2023094713A3 (en) Coronavirus vaccine
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
WO2023147092A3 (en) Coronavirus vaccine
Huang et al. Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
EP1917033A4 (en) VIRUS LIKE PARTICLES AS PARAMYXOVIRUS VACCINES
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
NO20054608L (no) Influensavirusvaksine
MX2020008394A (es) Tratamiento que usa arn que codifica citoquinas.
MX2019003682A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
NO20082149L (no) Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk
MX2022012251A (es) Vacuna universal contra la influenza usando arnm modificado con nucleósidos.
MX2022014167A (es) Replicón de arn que codifica una proteína de espícula del coronavirus estabilizada.
MX2019014674A (es) Virus recombinante de sarampion que expresa proteinas de virus zika y sus aplicaciones.
WO2021257510A3 (en) Measles virus vaccine expressing sars-cov-2 protein(s)
WO2005081716A3 (en) DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
MX2024006506A (es) Vacunas basadas en vectores virales de metapneumovirus humano.
WO2022103929A3 (en) Nucleic acids, proteins, and vaccines of sars-cov-2
MX2023012368A (es) Vacuna de virus.
MX390966B (es) Vacunas contra el dengue